|Videos|December 20, 2022
Adjuvant Nivolumab Therapy for MIBC: Safety and Efficacy Data from CheckMate 274
Author(s)Terence Friedlander, MD
Dr Terence Friedlander explains safety and efficacy data from the CheckMate 247 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC.
Advertisement
Episodes in this series
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5